中国人类乳头瘤病毒疫苗接种的机遇与挑战

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-04-04 DOI:10.1080/21645515.2024.2329450

Chao Zhao, Yun Zhao, Jingran Li, Mingzhu Li, Yujing Shi, Lihui Wei

{"title":"中国人类乳头瘤病毒疫苗接种的机遇与挑战","authors":"Chao Zhao, Yun Zhao, Jingran Li, Mingzhu Li, Yujing Shi, Lihui Wei","doi":"10.1080/21645515.2024.2329450","DOIUrl":null,"url":null,"abstract":"Current estimates of the HPV infection rate in China vary by geographic region (9.6–23.6%), with two age peaks in prevalence in women ≤20–25 years of age and 50–60 years of age. HPV-16, 52 and 58 a...","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"69 1","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Opportunities and challenges for human papillomavirus vaccination in China\",\"authors\":\"Chao Zhao, Yun Zhao, Jingran Li, Mingzhu Li, Yujing Shi, Lihui Wei\",\"doi\":\"10.1080/21645515.2024.2329450\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Current estimates of the HPV infection rate in China vary by geographic region (9.6–23.6%), with two age peaks in prevalence in women ≤20–25 years of age and 50–60 years of age. HPV-16, 52 and 58 a...\",\"PeriodicalId\":13058,\"journal\":{\"name\":\"Human Vaccines & Immunotherapeutics\",\"volume\":\"69 1\",\"pages\":\"\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Vaccines & Immunotherapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21645515.2024.2329450\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21645515.2024.2329450","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

目前估计的中国HPV感染率因地理区域而异（9.6%-23.6%），在≤20-25岁和50-60岁的女性中存在两个流行高峰。HPV-16、52和58是中国女性感染率最高的三种病毒。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Opportunities and challenges for human papillomavirus vaccination in China

Current estimates of the HPV infection rate in China vary by geographic region (9.6–23.6%), with two age peaks in prevalence in women ≤20–25 years of age and 50–60 years of age. HPV-16, 52 and 58 a...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

自引率

8.30%

发文量

审稿时长

1 months

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.